Expert Review of Neurotherapeutics

Psychosis in Parkinson's disease: how should we treat it?
pp. 1243-1246(4)
Authors: Shotbolt, Paul; Samuel, Michael; Anthony, David

New `risk-score' method to predict dementia
pp. 1247-1248(2)

Bupropion: pharmacology and therapeutic applications
pp. 1249-1265(17)
Authors: Foley, Kevin F; DeSanty, Kevin P; Kast, Richard E

Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy
pp. 1267-1274(8)
Authors: Živković, Saša A

Rotigotine for the treatment of Parkinson's disease
pp. 1275-1282(8)
Authors: Morgan, John C; Sethi, Kapil D

Zonisamide for the treatment of epilepsy
pp. 1283-1292(10)
Authors: Arzimanoglou, Alexis; Rahbani, Abdallah

Early diagnostics and therapeutics for Alzheimer's disease - how early can we get there?
pp. 1293-1306(14)
Authors: Monien, Bernhard H; Apostolova, Liana G; Bitan, Gal

Listening to hypochondriasis and hearing health anxiety
pp. 1307-1312(6)
Authors: Braddock, Autumn E; Abramowitz, Jonathan S

Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation
pp. 1313-1325(13)
Authors: Asanuma, Masato; Miyazaki, Ikuko

Impaired regulation of immune responses in cognitive decline and Alzheimer's disease: lessons from genetic association studies
pp. 1327-1336(10)
Authors: Chiappelli, Martina; Tumini, Emanuela; Porcellini, Elisa; Licastro, Federico

Ubiquitin proteasome system as a pharmacological target in neurodegeneration
pp. 1337-1347(11)
Authors: Hol, Elly M; Fischer, David F; Ovaa, Huib; Scheper, Wiep

Predictors of early mortality in patients with ischemic stroke
pp. 1349-1362(14)
Author: Kazmierski, Radoslaw

Review of the epidemiological literature on antidepressant use and breast cancer risk
pp. 1363-1374(12)
Author: Coogan, Patricia F

Innovations and recent trends in the treatment of ADHD
pp. 1375-1385(11)
Authors: Madaan, Vishal; Kinnan, Shannon; Daughton, Joan; Kratochvil, Christopher J